Can-Fite BioPharma Ltd. logo
Can-Fite BioPharma Ltd. CANF
$ 1.48 2.78%

Annual report 2023
added 12-21-2024

report update icon

Can-Fite BioPharma Ltd. Balance Sheet 2011-2024 | CANF

Annual Balance Sheet Can-Fite BioPharma Ltd.

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - - - -3.5 M -8.11 M -16.9 M -9.27 M -5.96 M -1.15 M -3.84 M

Long Term Debt

- - - - - - - - - - - - -

Long Term Debt Current

- - - 43 K - - - - - - - - -

Total Non Current Liabilities

1.73 M 2.31 M 3.14 M 2.18 M 2.46 M 1.82 M 2.98 M 3.79 M 5.38 M 1.85 M 37 K 18.2 K 258 K

Total Current Liabilities

2.02 M 2.5 M 2.73 M 1.27 M 3.27 M - - - - - - - -

Total Liabilities

- - - 3.45 M 7.3 M 4.94 M 4.78 M 6.29 M 7.16 M 3.33 M 2.18 M 2.34 M 1.61 M

Deferred Revenue

622 K 783 K 818 K 334 K 469 K 926 K 374 K 322 K 220 K - - - -

Retained Earnings

-158 M -151 M -141 M -125 M -110 M -101 M -106 M -91 M -82.7 M -78.1 M -80.5 M -67.3 M -60.8 M

Total Assets

9.99 M 9.28 M 20.3 M 9.52 M 8.17 M 7.95 M 7.83 M 10.2 M 17.6 M 10.2 M 6.63 M 1.64 M 4.9 M

Cash and Cash Equivalents

- - - 8.27 M 2.7 M - - - - - - - -

Book Value

- - 20.3 M 6.07 M 876 K 3.02 M 3.05 M 3.87 M 10.4 M 6.86 M 4.46 M -708 K 3.29 M

Total Shareholders Equity

6.24 M 4.47 M 14.4 M 6.07 M 2.44 M 3.02 M - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet Can-Fite BioPharma Ltd.

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - 71 K - 25 K - 24 K - 22 K - 39 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Non Current Liabilities

- - - - 3.14 M - 3.37 M - 2.18 M - 2.14 M - 2.46 M - - - 1.82 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - 818 K - 1 M - 334 K - - - 469 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - -141 M - -131 M - -125 M - -119 M - -110 M - - - -97.7 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 20.3 M - 9.68 M - 9.52 M - 12.8 M - 8.17 M - - - 7.95 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - 4.39 M - 7.54 M - 8.27 M - 9.06 M - 2.7 M - 8.2 M - 3.62 M - - - 3.5 M - - - 8.12 M - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - - - 20.3 M - 9.68 M - 9.52 M - 12.8 M - 8.17 M - - - 7.95 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 14.4 M - 3.96 M - 6.07 M - 9.16 M - 2.44 M - 8.44 M - 3.02 M - - - 2.98 M - - - 3.91 M - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency